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Abstract
Background: The fear of an early post-pancreatectomy haemorrhage (PPH) may prevent surgeons from
prescribing post-operative venous thromboembolism (VTE) chemoprophylaxis. The primary hypothesis of
this study was that the national post-pancreatectomy early PPH rate was lower than the rate of VTE. The
secondary hypothesis was that patients at high risk for post-discharge VTE could be identified, potentially
facilitating the selective use of extended chemoprophylaxis.
Patients and methods: All elective pancreatectomies were identified in the 2005 to 2010 American
College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP) database. Factors
associated with 30-day rates of (pre- versus post-discharge) VTE, early PPH (transfusions > 4 units within
72 h) and return to the operating room (ROR) with PPH were analysed.
Results: Pancreaticoduodenectomies (PD) and distal pancreatectomies (DP) numbered 9140 (66.4%)
and 4631 (33.6%) out of 13 771 pancreatectomies, respectively. Event rates included: VTE (3.1%), PPH
(1.1%) and ROR+PPH (0.7%). PD and DP had similar VTE rates (P > 0.05) with 31.9% of VTE occurring
post-discharge. Independent risk factors for late VTE included obesity [odds ratio (OR), 1.5], age  75
years (OR, 1.8), DP (OR, 2.4) and organ space infection (OR, 2.1) (all P < 0.02).
Conclusions: Within current practice patterns, post-pancreatectomy VTE outnumber early haemor-
rhagic complications, which are rare. The fear of PPH should not prevent routine and timely post-
pancreatectomy VTE chemoprophylaxis. Because one-third of VTE occur post-discharge, high-risk
patients may benefit from post-discharge chemoprophylaxis.
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Introduction
For most major abdominal operations, routine post-operative
venous thromboembolism (VTE) chemoprophylaxis has been
proven to be both safe and effective, and is now considered the
international standard of care, especially for cancer surgery.1–7
Post-operative VTE chemoprophylaxis in the form of low-dose
unfractionated heparin or low-molecular-weight heparin is a
Grade 1B recommendation from the most recent American
College of Chest Physicians (ACCP) guidelines, for all moderate-
to high-VTE-risk patients undergoing major abdominal surgery,
as long as there is no significant bleeding risk.1,2,8 In spite of this
recommendation, hepatopancreatobiliary (HPB) surgeons have
frequently withheld VTE chemoprophylaxis owing to the per-
ceived risk of peri-operative haemorrhage in liver and pancreatic
surgery. This traditional mentality has placed surgical HPB
patients, most of whom have cancer, at risk for the significant
morbidity and mortality associated with VTE.9,10
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As with all major abdominal surgery, pancreatic surgeons must
maintain a balance between the risk of intra- or post-operative
bleeding and the risk of VTE. In addition, pancreatic cancer
patients, who make up the majority of patients undergoing pan-
creatic surgery, have an intrinsically high risk of VTE.11,12 With
regard to bleeding risk, the true incidence of an early post-
pancreatectomy haemorrhage (PPH)13 has not been delineated
except in institutional studies.14 Nor has it been compared with
VTE event rates. In the absence of large-scale comparative data
regarding the incidence of bleeding and thrombosis,14 pancreatic
surgery patients have been treated based on the surgeon’s discre-
tion, with a variety of approaches to the initiation, timing and
duration of post-operative VTE chemoprophylaxis. We recently
reported that in liver surgery patients, the risk of VTE outweighed
the risk of early post-hepatectomy bleeding events.15 In the
present study, we sought to determine whether this paradigm held
true for pancreatectomies as well.
A second set of issues to address is the timing of post-
pancreatectomy VTE and the potential benefit of extended,
post-discharge, chemoprophylaxis.16 Several previous studies of
abdominal surgery patients have shown the value of extended
chemoprophylaxis in high-risk patients.8,17,18 Thus, in high-VTE-
risk cancer patients undergoing abdominal surgery, the ACCP
currently recommends 4 weeks of extended duration chemo-
prophylaxis if the risk of bleeding is not high (Grade 1B recom-
mendation).1 However, longer-term prescriptions of extended
chemoprophylaxis are associated with problems related to patient
quality of life, financial costs and potential bleeding risk. The most
tailored strategy would, therefore, be to focus extended chemo-
prophylaxis on only patients who are truly high risk and thus would
benefit most from the prescription. Before developing post-
discharge VTE prophylaxis recommendations, there is a need to
demonstrate that post-discharge VTE is a separate entity from
pre-discharge VTE and that post-discharge VTE comprises a clini-
cally relevant proportion of all post-operative VTE. Then there
must be identifiable risk factors (and a large enough study
cohort with sufficient events) to stratify patients into a high-risk
group who would potentially benefit the most from extended
chemoprophylaxis.
The primary hypothesis of the present study was that the
national post-pancreatectomy VTE rate was greater than the rates
of early PPH events. The secondary hypothesis was that a certain
subset of pancreatectomy patients was at high risk for post-
discharge VTE and that there were clinical factors that could be
used to select patients for extended chemoprophylaxis. To test these
hypotheses, this study was designed to evaluate the rates, timing
and risk factors for pre- and post-discharge VTE after a pancreati-
coduodenectomy (PD) and a distal pancreatectomy (DP).
Patients and methods
Data acquisition, patients, and definitions
From the American College of Surgeons-National Surgical
Quality Improvement Program (ACS-NSQIP) participant use file
for 2005 to 2010, all pancreatectomy procedures were selected.
After excluding emergency cases, enucleations, necrosectomies,
pancreatic biopsies, hyperthermic intraperitoneal chemotherapy
cases, islet cell transplants and ampullectomies, all remaining pan-
createctomies were included for analysis. For PD, this included
current procedural terminology (CPT) codes 48150, 48152, 48153
and 48154. For the purposes of the analysis, total pancreatecto-
mies (CPT 48155) were grouped with PD. A distal pancreatectomy
included CPT codes 48140, 48145 and 48146. CPT codes were
analysed from the primary CPT column as well as from any of the
concurrent procedure columns. CPT coding did not differentiate
between open and laparoscopic cases.
For thrombotic events within 30 days of a pancreatectomy, the
analysis focused on three post-operative NSQIP variables: deep
vein thrombosis (DVT), pulmonary embolism (PE) or a combi-
nation of the two. VTE was defined as a clinically detected DVT or
PE. When both DVT and PE occurred, the first instance of either
was considered the presenting VTE. The timing of VTE was com-
pared with discharge date and labelled as ‘early’ (pre-discharge)
versus ‘late’ (post-discharge).
For post-operative haemorrhagic events, the analysis focused
on two post-operative variables: post-operative ‘bleeding transfu-
sion’ which was defined by NSQIP as a transfusion of > 4 units
packed red blood cells (PRBC) within 72 h of surgery (early PPH)
and unplanned return to the operating room (ROR) combined
with bleeding transfusion (ROR with PPH). Risk factors for pre-
and post-discharge VTE were derived from analysis of all NSQIP-
collected clinical factors.
The pre-operative NSQIP risk factors that were assessed
included race, age, gender, performance status, weight/body mass
index, haematocrit, platelets, blood urea nitrogen, creatinine,
albumin, partial thrombin time, international normalized ratio,
bilirubin, white blood cell count, alkaline phosphatase, aspartate
aminotransferase, American Society of Anesthesiologists (ASA)
class, smoking, chronic obstructive pulmonary disease (COPD),
pneumonia, ascites, sepsis, disseminated cancer, diabetes, bleeding
disorder, pre-operative radiation therapy, pre-operative chemo-
therapy, pre-operative transfusion, pre-operative hospitalization
and a previous operation within 30 days.
Intra-operative variables included operative time, intra-
operative transfusion, type of pancreatectomy and concurrent
major operation. Concurrent major operations were defined as
adrenalectomy, gastrectomy, oesophagectomy, intestinal resection,
colorectal resection, retroperitoneal tumor resection, nephrec-
tomy and/or hepatectomy. The definition of major concurrent
operations did not include splenectomy, cholecystectomy, liver
wedge resection/biopsy, radiofrequency ablation, feeding tube
placement and abdominal wall hernia repair.
Thirty-day post-operative outcomes included a post-operative
transfusion, bleeding transfusion (early PPH), ROR, renal insuf-
ficiency or failure, respiratory failure, myocardial infarction,
cardiac arrest, surgical site infection, organ space infection
(OSI, including abscess or pancreatic leak), fascial dehiscence,
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post-operative sepsis or septic shock, length of stay and mortality.
As a result of the defined limitations of NSQIP data, post-
pancreatectomy mortality was defined as death within 30 postop-
erative days or death at a later date if the patient had a continuous
hospitalization from surgery to the death date.
Statistical analysis
The association of clinical factors with VTE, bleeding complica-
tions and mortality, was analysed using the chi-squared test or
Fisher’s exact test for non-parametric categorical data and the
Mann–Whitney U-test for non-parametric continuous data. Sig-
nificant univariate risk factors were entered into a multivariate
logistic regression model to determine independent associations.
Analyses were performed using SPSS Statistics 19 (IBM, Armonk,
NY, USA). All tests were two-sided. Statistical significance was
defined as P < 0.05.
Results
Patients and pancreatectomies analysed
From 2005 to 2010, 13 771 patients met the inclusion criteria with
a median age 64 years (range 16–90), 51.7% female gender and
78.6% Caucasian race. Rates of common pre-operative risk factors
included 66.5% with ASA class3, 19.7% with age 75 years and
26.9% with obesity [body mass index (BMI)  30 kg/m2]. The
case distribution included 9140 (66.4%) PD (including 306
(2.2%) total pancreatectomies) and 4631 (33.6%) DP. Indications
for surgery included malignant diagnoses in 81.7% of patients
with no difference in VTE rates between malignant and benign
indications (3.2% versus 2.9%, P = 0.451). Other clinically rel-
evant pre-, intra- and post-operative factors are described in
Table 1.
VTE, bleeding, and transfusions in relation to
type of pancreatectomy
Overall complication rates included the following: DVT (2.2%),
PE (1.2%), VTE (3.1%), PPH (1.1%) and ROR with PPH (0.6%).
There were only 5 (0.04%) patients who experienced both VTE
and PPH after a pancreatectomy. VTE event rates were more fre-
quent than PPH rates and/or ROR with PPH rates for both PD
(3.0%, 1.1%, 0.7%) and DP (3.3%, 1.0%, 0.5%, P < 0.001, Fig. 1).
Analysis of the association between the type of pancreatectomy
and complication rates showed no differences in bleeding or VTE
events, P = 0.362, Fig. 1. Intra-operative transfusions  1 unit
PRBC were common (28.7%), as were intra-operative transfu-
sions 2 units PRBC (21.6%), with PD transfusion rates (31.5%,
23.4%) higher than for DP (23.5%, 18.2%, respectively,P < 0.001).
Factors associated with early PPH
The univariate analysis of peri-operative factors associated with
early PPH, or bleeding transfusion, is detailed in Table 1. On
multivariate analysis, independent pre- and intra-operative
factors associated with early PPH included the following: ASA
class  3 [odds ratio (OR) 1.74, 95% confidence interval (CI)
1.08–2.79, P = 0.023], a lack of independent functional status (OR
2.10, 95% CI, 1.11–3.95, P = 0.023) and an intra-operative trans-
fusion  4 units PRBC (OR 6.16, 95% CI, 4.12–9.21, P < 0.001,
Table 2).
Factors associated with ROR with early PPH
The univariate analysis of peri-operative factors associated with
ROR with early PPH is detailed in Table 3. On multivariate analy-
sis, independent pre- and intra-operative predictors of ROR with
early PPH included the following: pre-operative sepsis (OR 2.77,
95% CI, 1.23–6.25, P = 0.014), a pre-operative bleeding disorder
(OR 2.83, 95% CI, 1.25–6.44, P = 0.013) and an intra-operative
transfusion  4 units PRBC (OR 6.09, 95% CI, 3.64–10.21, P <
0.001, Table 2).
Factors associated with 30-day mortality
The 30-day postoperative mortality rate was 2.6%. Comparisons
of risk factors for 30-day mortality are provided in Table 4. Inde-
pendent risk factors for 30-day mortality included age 80 years
(OR 2.56, 95% CI 1.723–3.79), pre-operative dyspnoea (OR 1.57,
95% CI 1.03–2.40), a lack of independent function (OR 2.14, 95%
CI 1.28–3.57), albumin <3.5 g/dl (OR 1.47, 95% CI 1.07–2.03), an
intra-operative transfusion  4 units PRBC (OR 2.65, 95% CI
1.81–3.88), PD (vs. DP, OR 1.87, 95% CI 1.26–2.77), unplanned
ROR (OR 4.35, 95% CI 3.00–6.29), post-operative acute renal
insufficiency/failure (OR 6.33, 95% CI 3.86–10.40), post-
operative pneumonia (OR 2.35, 95% CI 1.56–3.54), ventilator
need/failure to wean >48 h (OR 2.13, 95% CI 1.38–3.28) and early
PPH (OR 2.05, 95% CI 1.11–3.81). VTE was not an independent
factor for death.
Risk factors and timing of post-pancreatectomy VTE
Comparisons of risk factors for VTE are provided in Table 5.
Independent risk factors for any (either pre- or post-discharge)
VTE within 30 days of surgery are listed in Table 2. Major post-
operative complications associated with any VTE included OSI
(OR 1.72, 95% CI, 1.26–2.34, P = 0.001) and post-operative ven-
tilator requirement >48 h (OR 3.55, 95% CI 2.57–4.91). For PD,
the median date of diagnosis of OSI was post-operative day
(POD) 11, whereas for DP, it was POD 14. Relative to the median
discharge dates of POD 9 for PD and POD 7 for DP, the median
date of any VTE was POD 11, whereas it was POD13 for DP. Late
thromboembolic events accounted for 33.7%, 35.7% and 31.9%
of all observed DVT, PE, and VTE, respectively (Fig. 2). Among
patients with early VTE, the median date of VTE was POD 8 with
a median discharge date of POD 20. Among patients with late
VTE, the median date of VTE was POD 19 with a median dis-
charge date of POD 8.
Post-pancreatectomy VTE pre-discharge risk factors
Univariate factors associated with early VTE are detailed in
Table 6. Independent risk factors included a lack of independent
functional status (OR 1.78, 95% CI 1.05–2.99, P = 0.031),
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Table 1 Factors associated with early post-pancreatectomy haemorrhage (PPH, > 4 units blood in first 72 h after surgery)
Clinical Characteristic All patients (n = 13771) No early PPH
> 4 units
Early PPH
> 4 units
P
n or
median
% or
range
n or
median
% or
range
n or
median
% or
range
N 13771 13623 148
Pre-operative factors
BMI  40 kg/m2 537 3.9% 526 3.9% 11 7.4% 0.026
Dyspnoea 1210 8.8% 1189 8.7% 21 14.2% 0.020
Diabetes 3063 22.2% 3019 22.2% 44 29.7% 0.028
Lack of independent function 380 2.8% 366 2.7% 14 9.5% <0.001
Alcohol use 417 3.0% 417 3.1% 0 0% 0.031
Haematocrit <39% 7189 53.6% 7098 53.5% 91 65.0% 0.007
AST > 46 IU/l 3066 25.4% 3023 25.3% 43 34.1% 0.023
Albumin < 3.5 g/dl 3129 26.5% 3082 26.4% 47 38.2% 0.003
ASA class  3 9161 66.5% 9045 66.4% 116 78.4% 0.002
Disseminated cancer 495 3.6% 479 3.5% 16 10.8% <0.001
Bleeding disorder 382 2.8% 373 2.7% 9 6.1% 0.014
Intra-operative
Operative time, min 314 12–1146 246 12–892 313 12–1146 0.004
Operative time  360 min 5069 36.8% 5000 36.7% 69 46.6% 0.013
Any intra-operative transfusion 3002 28.7% 2910 28.3% 92 62.6% <0.001
RBC 4 718 6.9% 669 6.5% 49 33.3% <0.001
Concurrent Major GI/GU 990 7.2% 969 7.1% 21 14.2% 0.001
PD/total versus distal pancreatectomy 0.628
PD/total 9140 66.4% 9039 66.4% 101 68.2%
Distal 4631 33.6% 4584 33.6% 47 31.8%
Post-operative
Return to OR 921 6.7% 832 6.1% 89 60.1% <0.001
Sepsis/septic shock 1899 13.8% 1838 13.5% 61 41.2% <0.001
Acute renal insufficiency/failure 238 1.7% 217 1.6% 21 14.2% <0.001
Failure to wean ventilator 48 h 694 5.0% 633 4.6% 61 41.2% <0.001
Post-operative pneumonia 706 5.1% 674 4.9% 32 21.6% <0.001
Any SSI or organ space infection 2759 20.0% 2715 19.9% 44 29.7% 0.003
Organ space infection 1451 10.5% 1421 10.4% 30 20.3% <0.001
Cardiac arrest 151 1.1% 137 1.0% 14 9.5% <0.001
Severe complications 3436 25.0% 3313 24.3% 123 83.1% <0.001
Post-operative LOS 8 1–215 8 1–215 14 1–119 <0.001
Death within 30 days 357 2.6% 323 2.4% 34 23.0% <0.001
ASA, American Society of Anesthesiologists; AST, aspartate aminotransferase; BMI, body mass index; LOS, length of stay; OR, operating room;
RBC, (units) red blood cells; SSI, surgical site infection.
• Not significant: age, gender, race, platelets, sodium, blood urea nitrogen, creatinine, partial thrombin time, international normalized ratio, total
bilirubin, alkaline phosphatase, white blood cells, steroid use; chronic obstructive pulmonary disease; previous coronary stent; previous cardiac
surgery; medical hypertension; pre-operative sepsis; surgical peripheral vascular disease; smoking, pre-operative stroke, pre-operative radiation
therapy, operation in the preceding 30 days; pre-operative chemotherapy within 30 days; pre-operative weight loss  10%; dehiscence; superficial
SSI, deep SSI, venous thromboembolism.
• Not evaluated with < 1%: pre-operative pneumonia; ascites; varices; congestive heart failure; recent myocardial infarction; angina; rest pain,
pre-operative acute renal failure or dialysis; altered mental status; pre-operative open wound; pre-operative transfusion > 4 units; post-operative
MI, post-operative coma, post-operative stroke.
Severe complications include: pneumonia, reintubation, ventilator >48 h, renal insufficiency/failure, cardiac arrest, myocardial infarction, coma, stroke,
sepsis, septic shock, return to OR, wound dehiscence and organ space infection.
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pre-operative haematocrit < 39% (OR 1.69, 95% CI 1.17–2.43, P =
0.005), chronic obstructive lung disease (OR 1.74, 95% CI 1.01–
2.99, P = 0.046), pre-operative leukocytosis (OR 2.12, 95% CI
1.43–3.16, P < 0.001), disseminated cancer (OR 2.50, 95% CI
1.02–3.32, P = 0.040), bleeding disorder (OR 2.56, 95% CI 1.47–
4.44, P = 0.001), an intra-operative transfusion  2 units (OR
1.53, 95% CI 1.09–2.16, P = 0.014), operative time300 min (OR
1.44, 95% CI 1.02–2.03, P = 0.039), ventilator need/failure to wean
> 48 h (OR 3.74, 95% CI 2.42–5.77, P < 0.001) and OSI (OR1.64,
95% CI 1.10–2.45,P = 0.016). Patients with early VTE experienced
a 30-day mortality rate of 9.0% (versus 2.6% overall baseline
mortality rate, P < 0.001).
Post-pancreatectomy post-discharge VTE risk factors
Univariate factors associated with late VTE are detailed in Table 6.
Multivariate analysis identified the following independent risk
factors associated with post-discharge VTE: obesity (OR 1.53,
95% CI, 1.08–2.19, P = 0.018) and age  75 years (OR 1.76, 95%
Figure 1 Venous thromboembolism (VTE) events outnumber post-operative bleeding transfusions (post-pancreatectomy haemorrhage > 4
units in first 72 h after surgery) and returns to the operating room (ROR) with bleeding transfusions. There is no difference in the rates of
bleeding or thrombotic events between a pancreaticoduodenectomy and a distal pancreatectomy
Table 2 Independent factors associated with venous thromboembolism (VTE) and bleeding events after a pancreatectomy
Risk factor VTE Early PPH > 4 units ROR with early PPH
OR 95% CI P OR 95% CI p OR 95% CI P
Pre-operative
Haematocrit < 39% 1.46 1.13–1.88 0.003
Age  70 years 1.47 1.15–1.88 0.002
BMI  30 kg/m2 1.47 1.14–1.90 0.003
Bleeding disorder 1.93 1.17–3.18 0.010 2.77 1.23–6.25 0.014
Pre-operative sepsis 1.98 1.19–3.29 0.008 2.83 1.25–6.44 0.013
Disseminated cancer 2.12 1.36–3.32 0.001
ASA class  3 1.74 1.08–2.79 0.023
Lack independent function 2.10 1.11–3.95 0.023
Intra-operative
Operative time  360 min 1.30 1.02–1.65 0.048
Transfusion  4 units 6.16 4.12–9.21 <0.001 6.09 3.64–10.21 <0.001
Post-operative
Organ space infection 1.72 1.26–2.34 0.001
Ventilator > 48 h 3.55 2.57–4.91 <0.001
ASA, American Society of Anesthesiologists; BMI, body mass index; CI, confidence interval; OR, odds ratio; PPH, post-pancreatectomy
haemorrhage; ROR, return to operating room; VTE, venous thromboembolism.
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CI 1.20–2.58, P = 0.004), distal pancreatectomy (OR 2.41, 95% CI
1.71–3.39) and OSI (OR 2.14, 95% CI 1.39–3.28, P < 0.001). Of
the 136 patients with late VTE, 89 (65.4%) had at least one of these
4 risk factors. Patients with late VTE experienced a 30-day
mortality rate of 2.9% (versus 2.6% overall baseline mortality
rate, P = 0.579).
Discussion
The primary aims of this study were to compare the post-
operative rates of thromboembolic and bleeding events after
pancreatectomy and to identify risk factors for VTE, early PPH
and ROR with PPH, in patients undergoing PD and DP. Based on
standardized definitions and the presence of trained reviewers for
data collection, the ACS-NSQIP database was well-suited to
address each of these aims.15,19,20 This analysis determined that,
within the context of current national practice patterns, the risk of
VTE outweighs the risk of haemorrhagic events for both PD and
DP. In addition, the study identified unique risk factors for both
pre- and post-discharge VTE after pancreatic surgery. These data
suggest that late VTE is a clinically relevant complication after a
pancreatectomy with one-third of post-operative VTE occurring
Table 3 Factors associated with return to the operating room (ROR) and a post-pancreatectomy haemorrhage (PPH) > 4 units blood in the
first 72 h after surgery
Clinical characteristic All patients
(n = 13771)
No ROR with PPH
>4 units
ROR with PPH
>4 units
P
n or
median
% or
range
n or
median
% or
range
n or
median
% or
range
n 13771 13682 89
Pre-operative factors
Lack of independent function 380 2.8% 373 2.7% 7 7.9% 0.003
AST > 46 IU/l 3066 25.4% 3035 25.3% 31 39.7% 0.003
Alkaline phosphatase  126 IU/l 4411 36.6% 4376 36.6% 35 48.6% 0.035
Albumin < 3.5 g/dl 3129 26.5% 3097 26.4% 32 42.7% 0.002
ASA class  3 9161 66.5% 9091 66.4% 70 78.7% 0.015
Disseminated cancer 495 3.6% 487 3.6% 8 9.0% 0.006
Pre-operative sepsis 467 3.4% 459 3.4% 8 9.0% 0.003
Bleeding disorder 382 2.8% 375 2.7% 7 7.9% 0.003
Intra-operative
Operative time, min 314 12–1146 313 12–1146 358 81–892 0.021
Operative time  360 min 5069 36.8% 5026 36.7% 43 48.3% 0.024
Any intra-operative transfusion 3002 28.7% 2949 28.5% 53 59.6% <0.001
RBC  4 718 6.9% 689 6.7% 29 32.6% <0.001
Concurrent major GI/GU 990 7.2% 376 7.1% 14 15.7% 0.002
PD/total versus distal pancreatectomy 0.267
PD/total 9140 66.4% 9076 66.3% 64 71.9%
Distal 4631 33.6% 4606 33.7% 25 28.1%
Post-operative
Sepsis/septic shock 1899 13.8% 1858 13.6% 41 46.1% <0.001
Acute renal insufficiency/failure 238 1.7% 222 1.6% 16 18.0% <0.001
Failure to wean ventilator 48 h 694 5.0% 649 4.7% 45 50.6% <0.001
Post-operative pneumonia 706 5.1% 682 5.0% 24 27.0% <0.001
Organ space infection 1451 10.5% 1431 10.5% 20 22.5% <0.001
Cardiac arrest 151 1.1% 141 1.0% 10 11.2% <0.001
Post-operative LOS 8 1–215 8 1–215 13 1–73 <0.001
Death within 30 days 357 2.6% 334 2.4% 23 25.8% <0.001
ASA, American Society of Anesthesiologists; AST, aspartate aminotransferase; GI, gastrointestinal; GU, genitourinary; LOS, length of stay;
PD, pancreaticoduodenectomy; RBC, (units) red blood cells.
• Not significant: age, gender, race, body mass index, platelets, sodium, blood urea nitrogen, creatinine, partial thrombin time, international
normalized ratio, total bilirubin, white blood cells, steroid use; lung disease, dyspnoea, diabetes, previous coronary stent; previous cardiac surgery;
medical hypertension, alcohol use, smoking, pre-operative stroke, pre-operative radiation therapy, operation in preceding 30 days, pre-operative
chemotherapy, pre-operative weight loss  10%, dehiscence; superficial or deep surgical site infection, venous thromboembolism.
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Table 4 Factors associated with 30-day mortality after a pancreatectomy
Clinical characteristic All patients (n = 13771) No death Death P
n or
median
% or
range
n or
median
% or
range
n or
median
% or
range
N 13771 13414 357
Pre-operative factors
Age  80 years 1120 8.1% 1058 7.9% 62 17.4% <0.001
Male 6650 48.3% 6459 48.2% 191 53.5% 0.046
Dyspnoea 1210 8.8% 1150 8.6% 60 16.8% <0.001
Diabetes 3063 22.2% 2953 22.0% 110 30.8% <0.001
COPD 598 4.3% 569 4.2% 29 8.1% <0.001
Previous coronary stent 852 6.2% 809 6.0% 43 12.0% <0.001
Medical hypertension 7145 51.9% 6888 51.3% 257 72.0% <0.001
Lack of independent function 380 2.8% 342 2.5% 38 10.6% <0.001
> 10% weight loss 2186 15.9% 2103 15.7% 83 23.2% <0.001
Haematocrit <39% 7189 53.6% 6972 53.4% 217 62.7% 0.001
Alkaline phosphatase 126 IU/l 4411 36.6% 4270 36.4% 141 43.9% 0.006
AST > 46 IU/l 3066 25.4% 2952 25.1% 114 35.4% <0.001
PTT > 27 s 6806 67.5% 6606 67.4% 200 73.5% 0.032
BUN  20 mg/dl 2426 18.6% 2339 18.4% 87 25.1% 0.002
Creatinine  1.3 mg/dl 1129 8.5% 1068 8.2% 61 17.7% <0.001
Albumin < 3.5 g/dl 3129 26.5% 2982 26.0% 147 46.4% <0.001
Bilirubin > 1.0 mg/dl 3490 29.4% 3377 29.2% 113 37.3% 0.002
Steroid use 270 2.0% 257 1.9% 13 3.6% 0.020
ASA class  3 9161 66.5% 8848 66.0% 313 87.7% <0.001
INR  1.1 3920 34.0% 3776 33.7% 144 46.9% <0.001
Platelets < 150 000/ml 804 6.0% 772 5.9% 32 9.2% 0.012
Pre-operative sepsis 467 3.4% 436 3.3% 31 8.7% <0.001
Disseminated cancer 495 3.6% 472 3.5% 23 6.4% 0.003
Bleeding disorder 382 2.8% 366 2.7% 16 4.5% 0.046
Pre-operative radiation therapy 304 2.2% 289 2.2% 15 4.2% 0.009
Intra-operative
Operative time  360 min 5069 36.8% 4886 36.4% 183 51.3% <0.001
Any intra-operative transfusion 3002 28.7% 2863 28.1% 139 55.6% <0.001
RBC  4 718 6.9% 645 6.3% 73 29.2% <0.001
Concurrent major GI/GU 990 7.2% 946 7.1% 44 12.3% <0.001
PD/total versus distal pancreatectomy <0.001
Distal 4632 33.6% 4566 34.0% 66 18.5%
Post-operative
Early VTE 290 2.1% 264 2.0% 26 7.3% <0.001
Late VTE 136 1.0% 132 1.0% 4 1.1% 0.782
Any VTE 426 3.1% 396 3.0% 30 8.4% <0.001
Bleeding transfusion 148 1.1% 114 0.8% 34 9.5% <0.001
Any post-operative transfusion 916 6.7% 835 6.2% 81 22.7% <0.001
Return to OR 921 6.7% 769 5.7% 152 42.6% <0.001
Sepsis/septic shock 1899 13.8% 1714 12.8% 185 51.8% <0.001
Acute renal insufficiency/failure 238 1.7% 158 1.2% 80 22.4% <0.001
Failure to wean ventilator 48 h 694 5.0% 544 4.1% 150 42.0% <0.001
Post-operative pneumonia 706 5.1% 616 4.6% 90 25.2% <0.001
Dehiscence 224 1.6% 211 1.6% 13 3.6% 0.002
Organ space infection 1451 10.5% 1376 10.3% 75 21.0% <0.001
Cardiac arrest 151 1.1% 36 0.3% 115 32.2% <0.001
Severe complications (not VTE) 3436 25.0% 3130 23.3% 306 85.7% <0.001
ASA, American Society of Anesthesiologists; AST, aspartate aminotransferase; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal;
GU, genitourinary; INR, international normalized ratio; OR, operating room; PD, pancreaticoduodenectomy; PTT, partial thrombin time; RBC, (units) red blood cells;
VTE, venous thromboembolism.
• Not significant: body mass index; race, alcohol use; white blood cells, smoking, pre-operative stroke, operation in preceding 30 days; pre-operative chemotherapy within
30 days; superficial and deep surgical site infections.
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Table 5 Factors associated with no venous thromboembolism (VTE) compared with VTE
Clinical characteristic All patients (n = 13771) No VTE (DVT or PE) VTE (DVT or PE) P
n or
median
% or
range
n or
median
% or
range
n or
median
% or
range
N 13771 13345 426
Preoperative factors
Median age (range), years 64 16–90 64 16–90 66 20–90 0.004
Age 70 years 4572 33.2% 4407 33.0% 165 38.7% 0.014
BMI  30 kg/m2 3703 26.9% 3566 26.7% 137 32.2% 0.013
Dyspnoea 1210 8.8% 1156 8.7% 54 12.7% 0.004
COPD 598 4.3% 567 4.2% 31 7.3% 0.003
Steroid use 270 2.0% 256 1.9% 14 3.3% 0.045
Medical hypertension 7145 51.9% 6892 51.6% 253 59.4% 0.002
Lack of independent function 380 2.8% 349 2.6% 31 7.3% <0.001
Pre-operative sepsis 467 3.4% 441 3.3% 26 6.1% 0.002
INR > 1.0 5235 45.5% 5045 45.2 190 52.6% 0.005
Haematocrit < 39% 7189 53.6% 6928 53.3% 261 62.7% <0.001
WBC > 11 000/ml 1060 7.9% 1005 7.7% 55 13.2% <0.001
Albumin < 3.5 g/dl 3129 26.5% 2989 26.2% 140 38.3% <0.001
Disseminated cancer 495 3.6% 459 3.4% 36 8.5% <0.001
Bleeding disorder 382 2.8% 354 2.7% 28 6.6% <0.001
Neoplasm (versus benign) 8618 81.7% 8339 81.7% 279 83.3% 0.451
Intra-operative
Operative time, min 314 12–1146 313 12–1146 346 72–981 <0.001
Operative time  360 min 5069 36.8% 4872 36.5% 197 46.2% <0.001
Any intra-operative transfusion 3002 28.7% 2864 28.3% 138 41.1% <0.001
RBC  4 718 6.9% 671 6.6% 47 14.0% <0.001
Concurrent major operation 990 7.2% 945 7.1% 45 10.6% 0.006
PD/total versus distal pancreatectomy 0.362
PD/total 9140 66.4% 8866 66.4% 274 64.3%
Distal 4631 33.6% 4479 33.6% 152 35.7%
Post-operative
Any post-operative transfusion (<72 h) 916 6.7% 873 6.5% 43 10.1% 0.004
Return to OR (ROR) 921 6.7% 854 6.4% 67 15.7% <0.001
Sepsis/septic shock 1899 13.8% 1747 13.1% 152 35.7% <0.001
Acute renal insufficiency/failure 238 1.7% 223 1.7% 15 3.5% 0.004
Failure to wean ventilator 48 h 694 5.0% 613 4.6% 81 19.0% <0.001
Post-operative pneumonia 706 5.1% 644 4.8% 62 14.6% <0.001
Deep SSI 268 1.9% 253 1.9% 15 3.5% 0.017
Any SSI or organ space infection 2759 20.0% 2606 19.5% 153 35.9% <0.001
Organ space infection 1451 10.5% 1357 10.2% 94 22.1% <0.001
Fascial dehiscence 224 1.6% 208 1.6% 16 3.8% <0.001
Severe complications 3436 25.0% 3209 24.0% 227 53.3% <0.001
Post-operative LOS 8 1–215 8 1–215 14 1–98 <0.001
Death within 30 days 357 2.6% 327 2.5% 30 7.0% <0.001
BMI, body mass index; COPD, chronic obstructive pulmonary disease; DVT, deep venous thrombosis; INR international normalized ratio; LOS, length of
stay; OR, operating room; PD, pancreaticoduodenectomy; PE, pulmonary embolus; RBC, (units) red blood cells; SSI, surgical site infection; WBC, white
blood cells.
• Not significant: race, gender, American Society of Anesthesiologists score, platelets, sodium, blood urea nitrogen, creatinine, partial thrombin time, total
bilirubin, aspartate aminotransferase, alkaline phosphatase, previous coronary stent, previous cardiac surgery, alcohol use, smoking, diabetes, pre-
operative radiation therapy, operation in preceding 30 days, pre-operative chemotherapy; pre-operative weight loss  10%; post-operative bleeding
transfusion; superficial SSI.
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post-discharge. Finally, by isolating the risk factors for late VTE,
including obesity, age75 years, DP and/or OSI, the results of this
study provide a basis for identifying high-risk patients for selective
use of extended chemoprophylaxis.
There is general consensus that post-operative VTE chemo-
prophylaxis should be prescribed for all patients undergoing
major abdominal surgery if the patient’s acute bleeding risk is
acceptably lower than the thrombotic risk.1,2 The transferability of
these recommendations to complex HPB surgery, in which intra-
operative bleeding and intra-operative transfusions are common,
is less clear. To disprove or to corroborate historical fears of early
PPH, an accurate comparison of VTE and bleeding event rates
after a pancreatectomy is needed to determine the safety and
practicality of recommending routine post-operative VTE
chemoprophylaxis.
It is estimated that as many as 30% of pancreatic resections in
the United States are currently being performed at NSQIP
member institutions. By analysing a large national sampling of
patients, this study showed that early post-operative haemor-
rhagic events, although traditionally feared, are quite rare (<1%
event rate). Unlike early PPH which is likely related to intra-
operative technical issues,14 ongoing surgical bleeding, or uncor-
rected coagulopathy (all of which are contraindications for
immediately starting post-operative VTE chemoprophylaxis), late
PPH is generally related to abdominal sepsis, undrained pancre-
atic leaks and vascular pseudoaneurysms. Therefore, these unpre-
dictable late bleeding events may not represent a barrier to the
routine use of chemoprophylaxis. The number of patients who
experienced both VTE and PPH was extremely low (5 of 13 771),
to the point that detailed analysis of risk factors for this difficult
clinical scenario was not feasible.
The comparative rarity of early haemorrhagic events combined
with the higher risk of post-operative VTE in both PD and DP
make a very strong argument for routine and timely post-
operative chemoprophylaxis in all pancreatectomy patients.
Although early PPH is an independent risk factor for 30-day mor-
tality, its very low event rate is associated with the defined risk
factor of a major intra-operative transfusion (4 units pRBC). As
the most significant independent risk factor for early PPH or ROR
with PPH was an intra-operative transfusion 4 units PRBC, the
main exception to the regimented delivery of immediate post-
operative VTE chemoprophylaxis would be patients with ongoing
signs of active bleeding in the immediate post-operative period.
For these rare patients, haemostasis should be confirmed before
initiating VTE chemoprophylaxis.
There is ample evidence that institutional protocols for post-
operative (and even pre-induction dosing)21 have led to reduced
rates of post-operative VTE. However, there remains no consensus
on the length of post-operative therapy, even although extended
chemoprophylaxis is recommended for high-VTE-risk cancer
patients.1,2,8 Thus, many, if not most, surgeons subjectively discon-
tinue VTE chemoprophylaxis when patients meet discharge crite-
ria and leave the hospital. In order to comment on this practice, an
additional aim of this study was to examine the rates of and risk
factors for post-discharge VTE. The data from this analysis
provide a rationale for recommending extended chemoprophy-
laxis at least to obese and elderly patients, and those who experi-
ence significant post-operative complications such as OSI. In
addition, the analysis suggests that DP patients are more suscep-
tible to post-discharge VTE. There are a number of explanations
for this observation, but the most plausible is that pancreatic
fistulae are often identified later in the post-operative period after
DP compared with PD, and with the national trend of earlier
discharge of DP patients, more of these patients may develop this
important risk factor after leaving the hospital.22 Finally, malig-
nant diagnoses are typically associated with more post-operative
VTE compared with benign diseases, leading the ACCP to recom-
mend extended chemoprophylaxis for 30 days after major
abdominal cancer surgery in patients with a high VTE risk.
However, our data showed no difference among surgical patients
within 30 post-operative days, indicating that even patients
undergoing a pancreatectomy for non-malignant diagnoses may
benefit from extended VTE chemoprophylaxis.
A limitation of this study was that VTE chemoprophylaxis
usage was not a recorded variable in NSQIP.15,23 An assumption
can be made that many, but not all, patients received some
amount of inpatient post-operative chemoprophylaxis. The
timing of initiation would have been inconsistent. In contrast, it is
likely that post-discharge chemoprophylaxis was uncommonly
utilized, as it is not yet a current standard quality measure for
hospitalized or surgical patients, in spite of the ACCP recommen-
dations. NSQIP does not proactively screen asymptomatic
patients for VTE, and thus only clinically apparent VTE are
recorded. Another potential weakness is the limitation of the study
period to 30 days after surgery, which does not capture the full
post-operative risk of patients, especially cancer patients requiring
Figure 2 Approximately 1 in 3 post-pancreatectomy VTE events are
recognized post-discharge. (PE, pulmonary embolus; DVT, deep
venous thrombosis; VTE, venous thromboembolism)
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Table 6 Factors associated with no venous thromboembolism (VTE), early VTE, and late VTE, after a pancreatectomy
Clinical characteristic All patients
(n = 13 771)
No VTE
(DVT or PE)
Early (pre-
discharge) VTE
Late (post-
discharge) VTE
Early
versus
none
Late
versus
none
Early
versus
late
n or
median
% or
range
n or
median
% or
range
n or
median
% or
range
n or
median
% or
range
P P P
n 13771 100% 13345 96.9% 290 2.1 136 1.0%
Pre-operative factors
Median age (range), years 64 16–90 64 16–90 66 25–90 66 20–90 0.033 0.041 0.586
Age  75 years 2715 19.7% 2618 19.6% 60 20.7% 37 27.2% 0.649 0.027 0.135
BMI  30 kg/m2 3703 26.9% 3566 26.7% 86 29.7% 51 37.5% 0.264 0.005 0.106
Dyspnoea 1210 8.8% 1156 8.7% 34 11.7% 20 14.7% 0.068 0.013 0.389
COPD 598 4.3% 567 4.2% 25 8.6% 6 4.4% <0.001 0.925 0.119
Medical hypertension 7145 51.9% 6892 51.6% 169 58.3% 84 61.8% 0.025 0.019 0.494
Lack of independent function 380 2.8% 349 2.6% 26 9.0% 5 3.7% <0.001 0.410 0.050
Pre-operative sepsis 467 3.4% 441 3.3% 19 6.6% 7 5.1% 0.002 0.233 0.572
INR > 1.0 5235 45.5% 5045 45.2% 133 52.0% 57 54.3% 0.032 0.063 0.687
Haematocrit < 39% 7189 53.6% 6928 53.3% 193 68.7% 68 50.4% <0.001 0.494 <0.001
WBC > 11 000/ml 1060 7.9% 1005 7.7% 46 16.4% 9 6.7% <0.001 0.641 0.006
Albumin < 3.5 g/dl 3129 26.5% 2989 26.2% 117 46.8% 23 19.8% <0.001 0.122 <0.001
ASA class  3 9161 66.5% 8859 66.4% 212 73.1% 90 66.2% 0.016 0.959 0.142
Disseminated cancer 495 3.6% 459 3.4% 27 9.3% 9 6.6% <0.001 0.044 0.352
Bleeding disorder 382 2.8% 354 2.7% 23 7.9% 5 3.7% <0.001 0.415 0.099
Malignant (versus benign) 8618 81.7% 8339 81.7% 191 82.0% 88 86.3% 0.905 0.231 0.332
Intra-operative
Operative time, min 314 12–1146 313 12–1146 362 81–981 291 72–872 <0.001 0.160 <0.001
Operative time  300 min 7492 54.4% 7224 54.1% 206 71.0% 62 45.6% <0.001 0.047 <0.001
Any intra-operative
transfusion
3002 28.7% 2864 28.3% 115 48.9% 23 22.8% <0.001 0.217 <0.001
RBC  2 2256 21.6% 2138 21.2% 101 43.0% 17 16.8% <0.001 0.290 <0.001
RBC  4 718 6.9% 671 6.6% 41 17.4% 6 5.9% <0.001 0.779 0.005
Concurrent major operation 990 7.2% 945 7.1% 30 10.3% 15 11.0% 0.033 0.075 0.830
PD/total versus distal
pancreatectomy
0.017 <0.001 <0.001
PD/total 9140 66.4% 8866 66.4% 212 73.1% 62 45.6%
Distal 4631 33.6% 4479 33.6% 78 26.9% 74 54.4%
Post-operative
Any post-operative
transfusion (72 h)
916 6.7% 873 6.5% 36 12.4% 7 5.1% <0.001 0.512 0.020
Return to OR (ROR) 921 6.7% 854 6.4% 55 19.0% 12 8.8% <0.001 0.251 0.007
Sepsis/septic shock 1899 13.8% 1747 13.1% 117 40.3% 35 25.7% <0.001 <0.001 0.003
Acute renal insufficiency/
failure
238 1.7% 223 1.7% 15 5.2% 0 0% <0.001 0.178 0.007
Failure to wean ventilator 48 h 694 5.0% 613 4.6% 78 26.9% 3 2.2% <0.001 0.296 <0.001
Post-operative pneumonia 706 5.1% 644 4.8% 52 17.9% 10 7.4% <0.001 0.172 0.004
Superficial SSI 1141 8.3% 1095 8.2% 35 12.1% 11 8.1% 0.018 0.961 0.217
Deep SSI 268 1.9% 253 1.9% 12 4.1% 3 2.2% 0.006 0.746 0.406
Any SSI or OSI 2759 20.0% 2606 19.5% 111 38.3% 42 30.9% <0.001 0.001 0.138
OSI 1451 10.5% 1357 10.2% 67 23.1% 27 19.9% <0.001 <0.001 0.451
Fascial dehiscence 224 1.6% 208 1.6% 13 4.5% 3 2.2% <0.001 0.474 0.290
Severe complications 3436 25.0% 3209 24.0% 174 60.0% 53 39.0% <0.001 <0.001 <0.001
Post-operative LOS 8 1–215 8 1–215 20 7–98 8 3–24 0.001 0.017 <0.001
Death within 30 days 357 2.6% 327 2.5% 26 9.0% 4 2.9% <0.001 0.579 0.025
ASA, American Society of Anesthesiologists; BMI, body mass index; COPD, chronic obstructive pulmonary disease; DVT, deep venous thrombosis; INR, international
normalized ratio; LOS, length of stay; OR, operating room; OSI, organ space infection; PD, pancreaticoduodenectomy; PE, pulmonary embolus; RBC, (units) red blood cells;
SSI, surgical site infection; WBC, white blood cells.
• Not significant: race, gender, platelets, sodium, blood urea nitrogen, creatinine, partial thrombin time, total bilirubin, aspartate aminotransferase, alkaline phosphatase,
previous coronary stent; previous cardiac surgery; surgical peripheral vascular disease; alcohol use, smoking, diabetes, steroid use, pre-operative radiation therapy,
operation in preceding 30 days, pre-operative chemotherapy; pre-operative weight loss  10%; post-operative bleeding transfusion.
Bold type highlights univariate comparisons with P < 0.05.
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adjuvant chemotherapy. This specific risk would argue for
extended chemoprophylaxis for all cancer patients regardless of
the aforementioned risk factors, as a VTE can derail planned
adjuvant therapy. In spite of the weaknesses of NSQIP analyses,
the size of the cohort provided an event rate that powered a
multivariate analysis of VTE risk factors, which would be difficult
to accomplish with a smaller institutional sample or dataset.19,20 As
this is the first study to describe a subset of high-risk pancreatec-
tomy patients who might benefit from chemoprophylaxis beyond
discharge, further prospective studies are required to study the
clinical effectiveness and cost effectiveness of extended chemo-
prophylaxis after a pancreatectomy.
In conclusion, within current national practice patterns, post-
pancreatectomy VTE events outnumber major bleeding compli-
cations, which rarely occur. With the exception of patients with
overt ongoing bleeding, the fear of early PPH should not prevent
the timely administration of routine post-operative VTE for all
pancreatectomy patients. One-third of post-pancreatectomy VTE
occur post-discharge with clearly identifiable risk factors, poten-
tially providing a rationale for selective use of post-discharge VTE
chemoprophylaxis in high-risk patients.
Conflicts of interest
None declared.
References
1. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. (2012)
Executive summary: antithrombotic therapy and prevention of thrombo-
sis, 9th ed: American College of Chest Physicians Evidence-Based Clini-
cal Practice Guidelines. Chest 141 (2 Suppl.):7S–47S.
2. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR
et al. (2008) Prevention of venous thromboembolism: American College
of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th
Edition). Chest 133 (6 Suppl.):381S–453S.
3. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H.
(2001) Meta-analysis of low molecular weight heparin in the prevention
of venous thromboembolism in general surgery. Br J Surg 88:913–
930.
4. Collins R, Scrimgeour A, Yusuf S, Peto R. (1988) Reduction in fatal
pulmonary embolism and venous thrombosis by perioperative adminis-
tration of subcutaneous heparin. Overview of results of randomized trials
in general, orthopedic, and urologic surgery. N Engl J Med 318:1162–
1173.
5. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA et al.
(2012) Prevention of VTE in nonorthopedic surgical patients: antithrom-
botic therapy and prevention of thrombosis, 9th ed: American College of
Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest
141 (2 Suppl.):e227S–e277S.
6. Leonardi MJ, McGory ML, Ko CY. (2007) A systematic review of deep
venous thrombosis prophylaxis in cancer patients: implications for
improving quality. Ann Surg Oncol 14:929–936.
7. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ,
Rosendaal FR. (2006) Incidence of venous thrombosis in a large cohort of
66,329 cancer patients: results of a record linkage study. J Thromb
Haemost 4:529–535.
8. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner
B et al. (2013) International clinical practice guidelines for the treatment
and prophylaxis of venous thromboembolism in patients with cancer.
J Thromb Haemost 11:56–70.
9. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E et al.
(2006) A clinical outcome-based prospective study on venous thromboem-
bolism after cancer surgery: the @RISTOS project. Ann Surg 243:89–95.
10. Lyman GH. (2011) Venous thromboembolism in the patient with cancer:
focus on burden of disease and benefits of thromboprophylaxis. Cancer
117:1334–1349.
11. Horsted F, West J, Grainge MJ. (2012) Risk of venous thromboembolism
in patients with cancer: a systematic review and meta-analysis. PLoS
Med 9:e1001275.
12. Yhim HY, Jang MJ, Kwak JY, Yim CY, Choi WI, Lee YC et al. (2013) The
incidence, risk factors, and prognosis of recurrent venous thromboembo-
lism (VTE) in patients with advanced solid cancers receiving anticoagula-
tion therapy after the diagnosis of index VTE. ThrombRes 131:e133–e140.
13. Rahbari NN, Garden OJ, Padbury R, Maddern G, Koch M, Hugh TJ et al.
(2011) Post-hepatectomy haemorrhage: a definition and grading by the
International Study Group of Liver Surgery (ISGLS). HPB 13:528–535.
14. Correa-Gallego C, Brennan MF, D'Angelica MI, DeMatteo RP, Fong Y,
Kingham TP et al. (2012) Contemporary experience with postpancreate-
ctomy hemorrhage: results of 1,122 patients resected between 2006 and
2011. J Am Coll Surg 215:616–621.
15. Tzeng CW, Katz MH, Fleming JB, Pisters PW, Lee JE, Abdalla EK et al.
(2012) Risk of venous thromboembolism outweighs post-hepatectomy
bleeding complications: analysis of 5651 National Surgical Quality
Improvement Program patients. HPB 14:506–513.
16. MerkowRP, Bilimoria KY,McCarterMD,CohenME, Barnett CC, RavalMV
et al. (2011) Post-discharge venous thromboembolismafter cancer surgery:
extending the case for extended prophylaxis. Ann Surg 254:131–137.
17. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani
A et al. (2002) Duration of prophylaxis against venous thromboembolism
with enoxaparin after surgery for cancer. N Engl J Med 346:975–980.
18. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, Nielsen JD, Horn A,
Mohn AC et al. (2006) Prolonged prophylaxis with dalteparin to prevent
late thromboembolic complications in patients undergoing major
abdominal surgery: a multicenter randomized open-label study. J
Thromb Haemost 4:2384–2390.
19. Aloia TA, Fahy BN, Fischer CP, Jones SL, Duchini A, Galati J et al. (2009)
Predicting poor outcome following hepatectomy: analysis of 2313 hepa-
tectomies in the NSQIP database. HPB 11:510–515.
20. Strasberg SM, Hall BL. (2011) Postoperative morbidity index: a quanti-
tative measure of severity of postoperative complications. J Am Coll Surg
213:616–626.
21. Reinke CE, Drebin JA, Kreider S, Kean C, Resnick A, Raper S et al. (2012)
Timing of preoperative pharmacoprophylaxis for pancreatic surgery
patients: a venous thromboembolism reduction initiative. Ann Surg Oncol
19:19–25.
22. Baker MS, Bentrem DJ, Ujiki MB, Stocker S, Talamonti MS. (2011) Adding
days spent in readmission to the initial postoperative length of stay limits
the perceived benefit of laparoscopic distal pancreatectomy when com-
pared with open distal pancreatectomy. Am J Surg 201:295–299; discus-
sion 299-300.
23. Pitt HA, Kilbane M, Strasberg SM, Pawlik TM, Dixon E, Zyromski NJ et al.
(2009) ACS-NSQIP has the potential to create an HPB-NSQIP option.
HPB 11:405–413.
HPB 383
HPB 2014, 16, 373–383 © 2013 International Hepato-Pancreato-Biliary Association
